Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized genomics-guided targeted therapy or immunotherapy versus platinum-based chemotherapy in untreated cancer of unknown primary
MOH_2019-05-06_005949Phase 2Recruiting
- Sponsor
- Roche
- Start
- Feb 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, alectinib, vismodegib, entrectinib, ipatasertib and 11 more in cancer of unknown primary (CUP) (2 arms), sponsored by Roche. Primary endpoint: Not reported. Started Feb 2019; status: recruiting.
02
Drugs
atezolizumabalectinibvismodegibentrectinibipatasertib
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on MOH_2019-05-06_005949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-06_005949.